메뉴 건너뛰기
The Lancet Oncology
Volumn 14, Issue 11, 2013, Pages 1038-1039
Histone deacetylase inhibitors in multiple myeloma
Author keywords

[No Author keywords available]
Indexed keywords

BG 45; BORTEZOMIB; DEXAMETHASONE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; PANOBINOSTAT; PLACEBO; PROTEASOME INHIBITOR; RICOLINOSTAT; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;
EID: 84884702021     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70425-X     Document Type: Letter
Times cited : (4)
References (6)
  • 1
    • 9144220841 scopus 로고    scopus 로고
    • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    • Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004, 101:540-545.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 540-545
    • Mitsiades, C.S.1    Mitsiades, N.S.2    McMullan, C.J.3
  • 2
    • 84878519362 scopus 로고    scopus 로고
    • Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
    • Richardson PG, Mitsiades CS, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013, 37:829-837.
    • (2013) Leuk Res , vol.37 , pp. 829-837
    • Richardson, P.G.1    Mitsiades, C.S.2    Laubach, J.P.3
  • 3
    • 84884699420 scopus 로고    scopus 로고
    • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
    • published online Aug 15.
    • Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013, published online Aug 15. 10.1182/blood-2013-01-481325.
    • (2013) Blood
    • Richardson, P.G.1    Schlossman, R.L.2    Alsina, M.3
  • 4
    • 84884703399 scopus 로고    scopus 로고
    • Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
    • published online Sept 19.
    • Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013, published online Sept 19. http://dx.doi.org/10.1016/S1470-2045(13)70398-X.
    • (2013) Lancet Oncol
    • Dimopoulos, M.1    Siegel, D.S.2    Lonial, S.3
  • 5
    • 84858640254 scopus 로고    scopus 로고
    • Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selectiveHDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    • Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selectiveHDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119:2579-2589.
    • (2012) Blood , vol.119 , pp. 2579-2589
    • Santo, L.1    Hideshima, T.2    Kung, A.L.3
  • 6
    • 84895815366 scopus 로고    scopus 로고
    • Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma
    • published online Aug 5.
    • Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 2013, published online Aug 5. 10.1038/leu.2013.231.
    • (2013) Leukemia
    • Minami, J.1    Suzuki, R.2    Mazitschek, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.